REGENXBIO Inc. (RGNX) Form 424B5 — Jul 16, 2026

$RGNXForm 424B5Filed Jul 16, 2026, 4:32 PM ET0001193125-26-306170Original filing

REGENXBIO Inc. filed a preliminary prospectus supplement for a $100 million public offering of common stock to strengthen its balance sheet. The company reported preliminary cash position of approximately $105.5 million as of June 30, 2026, and expects to receive a $100 million milestone payment from AbbVie in July 2026. The capital raise comes as the company disclosed that its existing cash resources may not be sufficient to fund operations for the next 12 months, prompting substantial doubt about its ability to continue as a going concern without additional financing.

Key figures

Cash Position: $105.5 million
Gross Proceeds: $100,000,000
Shares Outstanding: 51,617,233
Net Tangible Book Value: $0.41
Abb Vie Milestone Payment: $100.0 million

Price after filing

1 day: -11.7%7 days: -8.5%30 days: -3.9%

Close on the filing date to close N calendar days later (from $11.20). Historical, not a forecast.

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.